Evommune Inc
EVMN
Company Profile
Business description
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Contact
1841 Page Mill Road
Suite 100
Palo AltoCA94304
USAT: +1 925 247-4481
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
48
Stocks News & Analysis
stocks
Is SpaceX a threat to this ASX giant?
Investors are raising concerns about the future of telecommunication connectivity in Australia.
stocks
Chart of the Week: This ASX top pick might be overlooked
ASX top pick remains cheap as investor concerns around wage costs might be overdone.
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,126.80 | 39.10 | -0.43% |
| CAC 40 | 8,431.84 | 1.05 | 0.01% |
| DAX 40 | 24,953.16 | 18.49 | 0.07% |
| Dow JONES (US) | 51,492.55 | 507.12 | -0.98% |
| FTSE 100 | 10,413.29 | 95.32 | -0.91% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,021.66 | 354.69 | -1.34% |
| Nikkei 225 | 71,053.49 | 1,151.24 | 1.65% |
| NZX 50 Index | 13,363.31 | 29.67 | -0.22% |
| S&P 500 | 7,420.10 | 91.25 | -1.21% |
| S&P/ASX 200 | 8,911.10 | 37.60 | -0.42% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |